Johnson & JohnsonJNJ
JNJ
About: Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Employees: 139,800
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
151% more first-time investments, than exits
New positions opened: 435 | Existing positions closed: 173
25% more call options, than puts
Call options by funds: $2.64B | Put options by funds: $2.11B
5% more funds holding
Funds holding: 3,832 [Q3] → 4,014 (+182) [Q4]
1.66% more ownership
Funds ownership: 70.16% [Q3] → 71.82% (+1.66%) [Q4]
6% less capital invested
Capital invested by funds: $273B [Q3] → $256B (-$16.5B) [Q4]
23% less funds holding in top 10
Funds holding in top 10: 189 [Q3] → 145 (-44) [Q4]
30% less repeat investments, than reductions
Existing positions increased: 1,330 | Existing positions reduced: 1,910
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$159
2%
upside
Avg. target
$168
8%
upside
High target
$181
16%
upside
6 analyst ratings
3 positive
50%
3 neutral
50%
0 negative
0%
Barclays Matt Miksic 48% 1-year accuracy 20 / 42 met price target | 6%upside $165 | Equal-Weight Maintained | 17 Apr 2025 |
Raymond James Jayson Bedford 44% 1-year accuracy 12 / 27 met price target | 5%upside $164 | Outperform Maintained | 16 Apr 2025 |
Morgan Stanley Terence Flynn 50% 1-year accuracy 11 / 22 met price target | 8%upside $169 | Equal-Weight Maintained | 16 Apr 2025 |
RBC Capital Shagun Singh 49% 1-year accuracy 33 / 68 met price target | 16%upside $181 | Outperform Reiterated | 16 Apr 2025 |
B of A Securities Tim Anderson 47% 1-year accuracy 7 / 15 met price target | 2%upside $159 | Neutral Maintained | 10 Apr 2025 |
Financial journalist opinion
Based on 126 articles about JNJ published over the past 30 days
Positive
CNBC
7 hours ago
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom
Tariff threats are fueling a new wave of U.S. manufacturing investments from the pharmaceutical industry.
Neutral
GlobeNewsWire
9 hours ago
FDA Approves Johnson & Johnson's IMAAVYTM (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for Families
First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older. First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older.
Positive
Reuters
14 hours ago
US FDA approves J&J's immune disorder drug
The U.S. Food and Drug Administration has approved Johnson & Johnson's drug to treat patients aged 12 years and older with an immune-mediated disorder, the drugmaker said on Wednesday.
Neutral
PRNewsWire
14 hours ago
Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)
First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older IMAAVY delivered rapid and substantial reduction in immunoglobulin G (IgG) levels, one of the root causes of gMG, in both the adult and pediatric pivotal studies gMG patients taking IMAAVY demonstrated 20 months of lasting disease control and symptom relief in the pivotal Vivacity-MG3 study and ongoing open-label extension (OLE) SPRING HOUSE, Pa. , April 30, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved IMAAVY™ (nipocalimab-aahu), a human FcRn-blocking monoclonal antibody, for the treatment of generalized myasthenia gravis (gMG).
Positive
Seeking Alpha
1 day ago
Best Dividend Aristocrats For May 2025
Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Edison (+25.65%), Cardinal Health (+17.82%), and Coca-Cola (+16.18%). 33 out of 69 Dividend Aristocrats have announced dividend increases in 2025, with an average growth rate of 4.33%.
Positive
Reuters
2 days ago
Trump to tout US investments from Nvidia, J&J, Hyundai, Toyota
CEOs and other executives from Nvidia , Johnson & Johnson , Toyota Motor , Eli Lilly and SoftBank Group are among the more than two-dozen senior business leaders slated to visit the White House on Wednesday as part of an event highlighting U.S. investments, officials told Reuters.
Positive
Seeking Alpha
2 days ago
My 10 Must-Own Dividend Stocks For Your Retirement Portfolio (One Yields 9.65%)
I present 10 must-own dividend stocks for your retirement portfolio to help you blend dividend income, growth and capital appreciation, designed to anchor a well-diversified dividend portfolio. Allianz, BlackRock, Microsoft and Visa offer strong potential for dividend growth and capital appreciation when investing over the long term. Chevron, Realty Income, and Ares Capital provide attractive Dividend Yields, aligning well with income-focused investment strategies for long term retirement planning.
Neutral
Business Wire
2 days ago
Johnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Bernstein's 41st Annual Strategic Decisions Conference on Wednesday, May 28th, 2025. Management will participate in a Fireside Chat at 10:00 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be a.
Positive
MarketBeat
2 days ago
3 Industry Behemoths Are Rewarding Investors With Dividend Bumps
In a market where investors are increasingly seeking stability and reliable returns, several industry giants have stepped up with significant dividend increases. Johnson & Johnson NYSE: JNJ, Costco Wholesale NASDAQ: COST, and NASDAQ NASDAQ: NDAQ have each announced meaningful hikes to their quarterly payouts, reinforcing their commitment to shareholder value even amid broader market volatility.
Negative
MarketBeat
2 days ago
3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.
Amid recession worries and tumbling markets; President Trump's tariffs are still helping the U.S. economy achieve key wins. Many huge corporations have announced plans to invest billions in U.S. manufacturing.
Charts implemented using Lightweight Charts™